MARKET

MYGN

MYGN

Myriad Genetics
NASDAQ
27.65
-0.20
-0.72%
After Hours: 27.65 0 0.00% 16:46 07/26 EDT
OPEN
28.25
PREV CLOSE
27.85
HIGH
28.27
LOW
27.21
VOLUME
1.42M
TURNOVER
0
52 WEEK HIGH
28.90
52 WEEK LOW
13.82
MARKET CAP
2.50B
P/E (TTM)
-9.8053
1D
5D
1M
3M
1Y
5Y
1D
U.S. RESEARCH ROUNDUP-Colgate-Palmolive, McKesson, Microsoft
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Colgate-Palmolive, McKesson, Microsoft and Air Products & Chemicals among those. AIG, AIG and others have seen their target prices cut by some analysts.
Reuters · 3d ago
Weekly Report: what happened at MYGN last week (0715-0719)?
Weekly Report · 4d ago
Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?
Myriad Genetics, Inc. (NASDAQ:MYGN) has US$38.7m of debt, but has more cash than debt. The company has more liabilities than assets, but its balance sheet is healthy. Myriad Genetics lost US$235m in the last year, but managed to grow its revenue by 11%. The company does carry debt, which is a risky sign for a company with a high level of debt. But the company's future is more important than its debt levels.
Simply Wall St · 07/17 16:55
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
63% of women do not know that there is an increased risk of breast cancer for women with dense breasts. Myriad Genetics, Inc. Released results from its nationwide Cancer Risk Survey: Breast Cancer Edition. The survey focused on understanding the role of breast density and cancer risk in the U.S.
Barchart · 07/17 07:00
U.S. RESEARCH ROUNDUP-BlackRock, Goldman Sachs, Netflix
Wall Street analysts revise ratings and price targets on several U.S.-listed companies. BlackRock, Goldman Sachs and Netflix revise their ratings and targets on Tuesday. Broadcom, Amazon.com and American Tower among companies with new targets. Some of the companies have announced stock splits.
Reuters · 07/16 07:29
MYRIAD GENETICS INC <MYGN.O>: TD COWEN RAISES TARGET PRICE TO $28 FROM $23
Reuters · 07/16 04:13
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
NASDAQ · 07/15 18:01
Weekly Report: what happened at MYGN last week (0708-0712)?
Weekly Report · 07/15 09:10
More
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.

Webull offers Myriad Genetics, Inc. stock information, including NASDAQ: MYGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MYGN stock methods without spending real money on the virtual paper trading platform.